^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    INHBA overexpression

    i
    Other names: INHBA, EDF, FRP
    Entrez ID:
    3624
    Related biomarkers:
    Mutation
    1year
    Molecular mechanisms and clinicopathological characteristics of inhibin βA in thyroid cancer metastasis. (PubMed, Int J Mol Med)
    In conclusion, INHBA may serve a pivotal role in promoting the aggressive phenotype of TC cells through modulating the RhoA/LIMK/cofilin signaling axis. These findings highlight INHBA as a potential biomarker and therapeutic target for the management of aggressive TC.
    Journal
    |
    RHOA (Ras homolog family member A) • INHBA (Inhibin, beta A)
    |
    INHBA overexpression
    over1year
    INHBA promotes tumor growth and induces resistance to PD-L1 blockade by suppressing IFN-γ signaling. (PubMed, Acta Pharmacol Sin)
    Furthermore, the activin A-specific antibody garetosmab improved anti-tumor immunity and its combination with the anti-PD-L1 antibody atezolizumab showed a superior therapeutic effect to monotherapy with garetosmab or atezolizumab. We demonstrate that INHBA and activin A are involved in anti-tumor immunity by inhibiting the IFN-γ signaling pathway, which can be considered as potential targets to improve the responsive rate of PD-1/PD-L1 blockade.
    Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • BRCA (Breast cancer early onset) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • INHBA (Inhibin, beta A)
    |
    PD-L1 expression • INHBA overexpression
    |
    Tecentriq (atezolizumab)
    almost2years
    INHBA is enriched in HPV-negative oropharyngeal squamous cell carcinoma and promotes cancer progression. (PubMed, Cancer Res Commun)
    Our results indicate that the upregulation of INHBA is tumor-promoting. We propose INHBA as an attractive therapeutic target for the treatment of INHBA-enriched tumors in HPV-negative OPSCC patients to ameliorate prognosis.
    Journal
    |
    CD8 (cluster of differentiation 8) • INHBA (Inhibin, beta A)
    |
    INHBA overexpression